Gilead Sciences, Inc.
NEWS
The company indicates the agency requested data from the MANTA and MANTA-Ray trials before completing its review of filgotinib. Here’s more about it.
Maryland has become a key part of the strategy for Kite, a Gilead company, and its mission to find a cure for cancer.
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
The U.S. Food and Drug Administration (FDA) approved Kite Pharma’s Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). Kite is a Gilead Science company.
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
Gilead Sciences reported additional data from its Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
JOBS
IN THE PRESS